Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Explore Changes in Cognitive, Clinical, Biological and Digital Measures Following 8 Weeks of Twice-daily Dosing of MT1988 and to Evaluate Safety & Tolerability of MT1988, in Participants at Clinical High Risk (CHR) for Psychosis

NCT07226895 is registered in ClinicalTrials.gov with Monument Therapeutics Limited as lead sponsor.

NCT NCT07226895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07226895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Explore Changes in Cognitive, Clinical, Biological and Digital Measures Following 8 Weeks of Twice-daily Dosing of MT1988 and to Evaluate Safety & Tolerability of MT1988, in Participants at Clinical High Risk (CHR) for Psychosis
Lead sponsor
Monument Therapeutics Limited
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 3, 2026
Completion date
October 31, 2027
Enrollment
150 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

clinical high risk for psychosis (chr)